SOTYKTU is an efficacious oral treatment that is generally well-tolerated1–4

DURABLE EFFICACY1

PASI 75 response rates were observed at
Week 24 and maintained at Week 521

GENERALLY WELL-TOLERATED

The most commonly reported adverse reaction is upper respiratory infection (18.9%).1 Less than 3% of patients discontinued treatment due to AEs between Weeks 0–161–4

ONCE DAILY, ORAL DOSING

Once-daily, oral treatment that can be taken with or without food, with no routine blood monitoring requirements after initiation and no identified DDIs1*

*Via enzyme inhibition, enzyme induction, or transporter inhibition.1
AE, adverse event; DDI, drug-drug interaction; PASI, Psoriasis Area and Severity Index.

unmet need

There is a need for advanced therapy options in psoriasis that can meet patients' needs,
and potentially ease the burden on the healthcare system5–14

What are the challenges currently faced by you and your care team?

Purple icon containing outline image of a group of people

Patients

Purple icon containing outline image of a hospital

Healthcare
services

Purple icon containing outline image of a doctor

Healthcare
professionals

Could SOTYKTU help you
overcome these challenges?

MOA

SOTYKTU is an oral, selective tyrosine kinase 2 (TYK2) inhibitor1,15

A diagram showing the mechanism of action for Sotyktu
  • TYK2 mediates signalling of IL-23, IL-12, and Type I IFN, which are naturally occurring cytokines involved in inflammatory and immune responses1,15
  • SOTYKTU binds to the regulatory domain of TYK2, stabilising an inhibitory interaction between the regulatory and the catalytic domains of the enzyme1,15
  • This results in allosteric inhibition of receptor-mediated activation of TYK2 and its downstream functions in cells1,15,16
  • SOTYKTU inhibits the release of proinflammatory cytokines and chemokines1,16

IFN, interferon; IL, interleukin; JAK, Janus kinase; MOA, mode of action; TYK2, Tyrosine Kinase 2.

References

  1. SOTYKTU. Summary of Product Characteristics.
  2. Armstrong A et al. J Am Acad Dermatol. 2023;88(1):29–39. Plus supplementary material.
  3. Strober B et al. J Am Acad Dermatol. 2023;88(1):40–51. Plus supplementary material.
  4. SOTYKTU. European Product Assessment Report (EPAR). 26 January 2023. Available at https://www.ema.europa.eu/en/documents/assessment-report/sotyktu-epar-public-assessment-report_en.pdf (Accessed August 2023).
  5. Kouwenhoven TA et al. J Dermatolog Treat. 2020; 31(1):13–17.
  6. Feldman S et al. Am Health Drug Benefits. 2016; 9(9):504–513.
  7. Smith CH et al. Br J Dermatol. 2020; 183(4):628–637.
  8. Schaarschmidt M-L et al. Arch Dermatol. 2011; 147(11):1285–1294.
  9. NHS North Central London. High Cost Drug Treatment Pathway for Psoriasis. 2020. Available at https://www.ncl-mon.nhs.uk/faq/guidelines/ (Accessed August 2023).
  10. Green W et al. Dermatology and Therapy. 2021; 11:1635–1642.
  11. NHS Berkshire West. Biologic DMARDs / Janus kinase inhibitors (JAKinib) / PDE4i Drug Monitoring Summary (Rheumatology/ Gastroenterology/ Dermatology). 2019. Available at https://www.berkshirewestccg.nhs.uk/about-us/our-responsibilities/medicines-optimisation-team/apc-documents/dawn-monitoring-summaries/ (Accessed August 2023).
  12. NHS England. Consultant-led Referral to Treatment Waiting Times. Incomplete pathways. February 2022. Available at https://www.england.nhs.uk/statistics/statistical-work-areas/rtt-waiting-times/ (Accessed August 2023).
  13. NHS England. Consultant-led Referral to Treatment Waiting Times. Incomplete pathways. February 2019. Available at https://www.england.nhs.uk/statistics/statistical-work-areas/rtt-waiting-times/ (Accessed August 2023).
  14. Thomas S et al. More than Skin Deep: The Underlying Burdens of Psoriasis and Psoriatic Arthritis. 2021. Available at: https://wilmingtonhealthcare.com/More-than-skin-deep-the-underlying-burdens-of-psoriasis-and-psoriaticarthritis/ (Accessed August 2023).
  15. Chimalakonda A et al. Dermatol Ther (Heidelb). 2021; 11(5): 1763–1776.
  16. Burke JR et al. Sci Transl Med. 2019;11(502). doi:10.1126/scitranslmed.aaw1736.
Legal Notice | Privacy Policy

© 2023 Bristol-Myers Squibb Company. All rights reserved.

Date of preparation: September 2023 | Job code: 1787-GB-2200015

© 2023 Bristol-Myers Squibb Company. All rights reserved.

Job code: 1787-GB-2200015 Date of preparation: September 2023

Adverse events should be reported. Reporting forms and information can be found at: UK - www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Ireland-via HPRA Pharmacovigilance at www.hpra.ie. Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK); 1800 749 749 (Ireland).